| Literature DB >> 35582066 |
Adekunle B Rowaiye1, Angus Nnamdi Oli2, Olukemi A Onuh1, Nkoli W Emeter1, Doofan Bur1, Oluwaseun A Obideyi1, Oluyomi Cornelius Dayisi1, Jude N Akpa1, Lovelyn Birah1, Edward E Omaka1, Frances Otibhor Iseghohi1, Akinbobola Peace Otitoju1, Philip F Uzor3, Jude Nnaemeka Okoyeh4.
Abstract
Background: The 2'-O-methyltransferase is responsible for the capping of SARS-CoV-2 mRNA and consequently the evasion of the host's immune system. This study aims at identifying prospective natural inhibitors of the active site of SARS-CoV-2 2'O-methyltransferase (2'-OMT) through an in silico approach. Materials and methods: The target was docked against a library of natural compounds obtained from edible African plants using PyRx - virtual screening software. The antiviral agent, Dolutegravir which has a binding affinity score of -8.5 kcal mol-1 with the SARS-CoV-2 2'-OMT was used as a standard. Compounds were screened for bioavailability through the SWISSADME web server using their molecular descriptors. Screenings for pharmacokinetic properties and bioactivity were performed with PKCSM and Molinspiration web servers respectively. The PLIP and Fpocket webservers were used for the binding site analyses. The Galaxy webserver was used for simulating the time-resolved motions of the apo and holo forms of the target while the MDWeb web server was used for the analyses of the trajectory data.Entities:
Keywords: 2’-O-methyltransferase Inhibition; COVID-19; Computational Drug prediction; Coronavirus disease; SARS-CoV-2
Year: 2022 PMID: 35582066 PMCID: PMC9097307 DOI: 10.21010/Ajid.v16i2.9
Source DB: PubMed Journal: Afr J Infect Dis ISSN: 2006-0165
Figure 1(A) the crystal structure of SARS-CoV-2 2′-OMT (cartoon model): Beta sheets in magentas, Alpha helix in cyan, and Loops in pink. (B) Surface representation of the target
Figure 2Ramanchandran diagram of the target
Figure 3The 3-dimensional structures of the standard and leads (stick model) (A) Dolutegravir (B) Isopteropodin (C) Rhamnetin
Molecular descriptors of standard and leads
| Variables | Dolutegravir (Standard) | Isopteropodin | Rhamnetin |
|---|---|---|---|
|
| 419.38 | 368.4 | 316.26 |
|
| 2.40 | 1.6 | 1.9 |
|
| 2 | 1 | 4 |
|
| 8 | 5 | 7 |
|
| 30 | 27 | 23 |
|
| 3 | 2 | 2 |
|
| 99.2 | 67.9 | 116 |
|
| 104.48 | 106.47 | 82.5 |
|
| 0.05 | 0.37 | - 0.11 |
|
| -0.20 | 0.25 | - 0.27 |
|
| -0.04 | - 0.34 | 0.21 |
|
| -0.20 | 0.07 | 0.27 |
|
| 0.04 | - 0.02 | - 0.27 |
|
| 0.07 | - 0.02 | 0.2 |
ADMET properties of ligands
| Variables | Dolutegravir (Standard) | Isopteropodin | Rhamnetin |
|---|---|---|---|
|
| -3.139 | -3.521 | -3.212 |
|
| 1.133 | 1.119 | -0.361 |
|
| 74.36 | 96.483 | 80.214 |
|
| -2.839 | -3.767 | -2.735 |
|
| Yes | Yes | Yes |
|
| No | No | No |
|
| No | No | No |
|
| -0.069 | 0.845 | 0.419 |
|
| 0.169 | 0.357 | 0.073 |
|
| -1.02 | 0.035 | -1.345 |
|
| -3.614 | -2.307 | -3.235 |
|
| No | No | No |
|
| Yes | Yes | No |
|
| No | No | Yes |
|
| No | No | No |
|
| No | No | No |
|
| No | No | No |
|
| No | No | No |
|
| -0.062 | 0.886 | 0.473 |
|
| No | Yes | No |
|
| No | No | No |
|
| 0.035 | -1.088 | 0.56 |
|
| No | No | No |
|
| No | No | No |
|
| 1.921 | 2.763 | 2.453 |
|
| 1.393 | 1.771 | 2.679 |
|
| Yes | Yes | No |
|
| No | No | No |
|
| 0.301 | 0.526 | 0.331 |
|
| 3.1 | -0.364 | 1.885 |
Figure 4Binding site of the target interacting with the standard and leads. (a) 2’-OMT-Dolutegravir complex, (b) 2’-OMT-Isopteropodin complex (c) 2’-OMT-Rhamnetin complex
Analysis of Hydrogen bonds
| A | Complexes | No. of bonds | Residues | Distance (H-A) | Distance (D-A) | Bond angle | |
|---|---|---|---|---|---|---|---|
| 2’-OMT- Dolutegravir | 4 | ASN43 | 3.33 | 3.82 | 111.15 | ||
| GLY71 | 2.35 | 3.02 | 125.93 | ||||
| SER74 | 2.96 | 3.66 | 125.37 | ||||
| TYR132 | 2.66 | 3.4 | 129.64 | ||||
| 2’-OMT- Isopteropodin | 4 | TYR30 | 2.41 | 2.97 | 116.73 | ||
| ASN43 | 2.97 | 3.33 | 101.14 | ||||
| GLY71 | 2.74 | 3.42 | 123.96 | ||||
| LYS170 | 3.19 | 3.98 | 135.16 | ||||
| 2’-OMT- Rhamnetin | 7 | TYR30 | 3.51 | 3.84 | 102.71 | ||
| ASN43 | 3.12 | 3.81 | 130.06 | ||||
| ASN43 | 2.78 | 3.15 | 101.72 | ||||
| LYS46 | 3.23 | 3.92 | 126.29 | ||||
| SER74 | 2.35 | 2.85 | 111.48 | ||||
| LYS170 | 2.64 | 3.28 | 121.36 | ||||
| GLU203 | 3.27 | 3.86 | 122.83 | ||||
|
|
|
|
|
| |||
|
|
|
|
|
|
| ||
| 2’-OMT- Isopteropodin | LYS170 | 4.19 | |||||
| 2’-OMT- Dolutegravir | ASN43 | 3.4 | |||||
| LYS76 | 3.62 | ||||||
| PRO80 | 3.58 | ||||||
| 2’-OMT- Rhamnetin | TYR30 | 3.98 | TYR132 | 4.27 | |||
| LYS170 | 3.8 | ||||||
| THR172 | 3.31 | ||||||
From Table 3B, 2’-OMT-Dolutegravir and 2’-OMT-Rhamnetin complexes both have three hydrophobic interacts each. The 2’-OMT- Isopteropodin and 2’-OMT-Rhamnetin complexes each have a salt bridge and a p-stacking respectively.
MDS of the apo and holo forms of the target (a summary)
| MDS Parameters | 2’-OMT-Apo | 2’-OMT -Dolutegravir | 2’-OMT - Isopteropodine | 2’-OMT -Rhamnetin |
|---|---|---|---|---|
|
| ||||
|
| 36.716 | 33.169 | 37.545 | 34.782 |
|
| 1.748 | 1.579 | 1.788 | 1.656 |
|
| 0 | 0 | 0 | 0 |
|
| 2.328 | 1.96 | 2172 | 2.047 |
|
| 21 | 13 | 19 | 16 |
|
| 1 | 1 | 1 | 1 |
|
| ||||
|
| 1 | 1 | 1 | 1 |
|
| 0 | 0 | 0 | 0 |
|
| 4 | 6 | 1 | 1 |
|
| 7 | 14 | 15 | 17 |
|
| 9 | 0 | 4 | 2 |
|
| 0 | 0 | 0 | 0 |
|
| 0 | 0 | 0 | 0 |
|
| ||||
|
| 260.75 | 250.96 | 236.79 | 251.62 |
|
| 0.87 | 0.84 | 0.79 | 0.84 |
|
| 9.83 | 10.01 | 10.31 | 12.16 |
|
| 0.66 | 0.67 | 0.69 | 0.75 |
|
| 0.33 | 0.30 | 0.29 | 0.34 |
|
| 6.21 | 4.93 | 5.47 | 5.31 |
|
| 5.88 | 4.62 | 5.18 | 4.97 |
|
| ||||
|
| 12.14 | 12.92 | 11.71 | 12.4 |
|
| 0.04 | 0.04 | 0.04 | 0.04 |
|
| 0.39 | 0.52 | 0.45 | 0.59 |
|
| 0.02 | 0.03 | 0.03 | 0.04 |
|
| PC3 | PC2 | PC2 | PC3 |
|
| PC2 | PC3 | PC2 | PC1 |
|
| 44.10% | 36.31% | 33.66% | 29.49% |
|
| 10.91% | 12.69% | 16.90% | 17.00% |
|
| 7.55% | 8.84% | 10.15% | 10.70% |
|
| 62.56% | 57.84% | 60.71% | 57.19 |
|
| 0.81 | 0.6 | 0.85 | 0.86 |
|
| 0.15 | 0.12 | 0.75 | 0.37 |
|
| 0.29 | 0 | 0.09 | 0.27 |
|
| ||||
|
| 121.79 | 109.77 | 107.41 | 133.92 |
|
| 94.36 | 78.87 | 98.59 | 113.75 |
|
| ||||
|
| 3.5926 | 3.5863 | 3.5865 | 3.5922 |
|
| 3.59856 | 3.59305 | 3.59251 | 3.60286 |
|
| 3.58136 | 3.57493 | 3.58255 | 3.58148 |
|
| 0.0172 | 0.0181 | 0.00996 | 0.02138 |
|
| 0.48 | 0.5 | 0.28 | 0.6 |
|
| 16 | 19 | 19 | 20 |
|
| 1 | 1 | 16 | 1 |